MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Vanda Pharmaceuticals ROCE Ratio 2011-2026 | VNDA
Annual ROCE Ratio Vanda Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.2 | -7.55 | -2.56 | 1.2 | 8.35 | 6.01 | 5.38 | 7.79 | -12.51 | -11.6 | -24.85 | -35.11 | -18.46 | -27.35 | -7.09 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.35 | -46.2 | -10.97 |
Quarterly ROCE Ratio Vanda Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.0 | -13.96 | -5.6 | -6.7 | -5.78 | -4.44 | -1.26 | -0.5 | 1.36 | 2.57 | -0.09 | 2.1 | 3.54 | 5.43 | 6.97 | 9.28 | 8.8 | 8.25 | 6.01 | 4.74 | 5.65 | 6.03 | 5.55 | 7.84 | 7.49 | 6.5 | 7.89 | 2.93 | -3.08 | -5.96 | -12.87 | -11.73 | -8.48 | -10.66 | -14.14 | -24.84 | -31.51 | -31.97 | -30.21 | 24.32 | 30.6 | 21.26 | 12.47 | -48.52 | -59.93 | -54.23 | -48.05 | -95.29 | -137.44 | -211.34 | -284.96 | -237.71 | -193.08 | -115.97 | -31.99 | -9.84 | -4.52 | 0.02 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 | -284.96 | -27.22 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
-5.86 | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
-188.87 | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Pharming Group N.V.
PHAR
|
281.39 | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
-161.2 | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Benitec Biopharma
BNTC
|
-10.11 | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Inventiva S.A.
IVA
|
-23.77 | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
-44.72 | $ 1.21 | -3.97 % | $ 71.5 M | Britain |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
-704.42 | $ 2.28 | -0.44 % | $ 1.03 M | Israel |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
|
Foghorn Therapeutics
FHTX
|
79.62 | $ 5.0 | 2.25 % | $ 315 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
6.73 | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
742.61 | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | USA |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
14.24 | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
-20.47 | $ 3.34 | -4.02 % | $ 116 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-107.87 | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Cabaletta Bio
CABA
|
-31.61 | $ 2.94 | -3.29 % | $ 3.43 M | USA |
 |
Iterum Therapeutics
ITRM
|
458.12 | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |